Invalidity dossier
US 12060590
PH20 polypeptide variants, formulations and uses thereof
Current assignee: Halozyme Inc
Added 10/15/2026, 6:01:06 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US12060590B2
Title: PH20 polypeptide variants, formulations and uses thereof
Patent number: US12060590B2 (application US18/068,218; pre-grant publication US20230295593A1)
Assignee/Applicant: Halozyme Inc (also listed: Halozyme Therapeutics Inc). Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor.
Key dates: Priority date 2011-12-30; filing date 2022-12-19; publication date 2024-08-13; legal status listed as Active, with adjusted expiration 2032-12-28.
Purpose and plain-language scope: The patent concerns PH20 polypeptide variants, formulations, and uses thereof. PH20 is classified as a hyaluronoglucosaminidase (hyaluronidase, enzyme class 3.2.1.35) — an enzyme that degrades hyaluronic acid. The classification data place the subject matter in enzyme compositions (C12N9/2474) and in medicinal preparations containing peptides, enzymes, and hydrolases (A61K38/47), including injectable and subcutaneous forms (A61K9/0019), combinations of active ingredients (A61K45/06), and uses relating to respiratory, ophthalmic, and anti-inflammatory indications (A61P11/00, A61P27/02, A61P29/00).
The excerpt's prior-art keywords — "position corresponding," "polypeptide," "modified," "agent," "amino acid" — suggest variants defined by amino-acid modifications at specified positions, but the excerpt does not contain the actual claims or a written description, so the precise variant scope cannot be stated from this text alone.
What the excerpt does not establish: It contains no claim language, sequence listings, examples, or written description. It therefore does not establish the specific amino-acid substitutions, the formulation components, the therapeutic methods claimed, or the metes and bounds of the claims. The listed "prior art date" and "priority date" are expressly noted in the source as assumptions, not legal conclusions. Legal status is likewise an assumption, not an analysis.
Source: https://patents.google.com/patent/[US12060590](/patent/US12060590)/en
Generated 10/15/2026, 6:10:48 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 12060590. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.